- Home
- HGTY vs ADPT Comparison
HGTY vs ADPT Comparison
Compare HGTY & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGTY
- ADPT
- Stock Information
- Founded
- HGTY 1984
- ADPT 2009
- Country
- HGTY United States
- ADPT United States
- Employees
- HGTY N/A
- ADPT N/A
- Industry
- HGTY Specialty Insurers
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HGTY Finance
- ADPT Health Care
- Exchange
- HGTY Nasdaq
- ADPT Nasdaq
- Market Cap
- HGTY 995.8M
- ADPT 1.2B
- IPO Year
- HGTY N/A
- ADPT 2019
- Fundamental
- Price
- HGTY $10.03
- ADPT $8.27
- Analyst Decision
- HGTY Hold
- ADPT Buy
- Analyst Count
- HGTY 3
- ADPT 5
- Target Price
- HGTY $11.00
- ADPT $9.10
- AVG Volume (30 Days)
- HGTY 40.4K
- ADPT 1.5M
- Earning Date
- HGTY 03-04-2025
- ADPT 02-11-2025
- Dividend Yield
- HGTY N/A
- ADPT N/A
- EPS Growth
- HGTY N/A
- ADPT N/A
- EPS
- HGTY 0.11
- ADPT N/A
- Revenue
- HGTY $1,153,350,000.00
- ADPT $178,957,000.00
- Revenue This Year
- HGTY $20.97
- ADPT $20.67
- Revenue Next Year
- HGTY $14.55
- ADPT $21.79
- P/E Ratio
- HGTY $94.63
- ADPT N/A
- Revenue Growth
- HGTY 21.13
- ADPT 5.10
- 52 Week Low
- HGTY $8.27
- ADPT $2.28
- 52 Week High
- HGTY $12.35
- ADPT $8.95
- Technical
- Relative Strength Index (RSI)
- HGTY 50.48
- ADPT 58.94
- Support Level
- HGTY $9.92
- ADPT $8.09
- Resistance Level
- HGTY $10.23
- ADPT $8.69
- Average True Range (ATR)
- HGTY 0.34
- ADPT 0.64
- MACD
- HGTY 0.02
- ADPT -0.00
- Stochastic Oscillator
- HGTY 58.67
- ADPT 65.66
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).